drugset / Trial / NCT03263208
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Phase 1/2
Unknown
20 enrolled
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+ leukemia.
Timeline
- Start
- 2017-08-16
- Primary completion
- 2019-01
- Completion
- 2019-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 0.6 g | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |